New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
09:08 EDTSNY, ALNYAlnylam deal with Sanofi positive, says JMP Securities
After Alnylam (ALNY) announced that Sanofi (SNY) would buy a 12% stake in it, while the two companies will enhance their cooperation, JMP Securities believes the deal provides Alnylam with significant pipeline and platform leverage. The firm also believes that the deal reduces the company's risk and increases its potential return;. JMP Securities reiterates an Outperform rating on the stock.
News For ALNY;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
07:43 EDTSNYExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
05:41 EDTSNYSanofi sees FY15 business EPS to be stable to slightly growing vs. 2014
The positive currency impact on 2015 full-year business EPS is estimated to be approximately 12%, under the assumption that exchange rates remain stable in the following three quarters at the average rates of March 2015.
05:40 EDTSNYSanofi reports Q1 business EPS 1.32 vs. EUR 1.17 last year
Subscribe for More Information
April 28, 2015
05:30 EDTSNYGenzyme says FDA grants fast track designation for development of GZ/SAR402671
Genzyme, a Sanofi company, announced that the FDA has granted Fast Track designation for the development of GZ/SAR402671, a new investigational oral substrate reduction therapy for the treatment of Fabry disease. FDAs Fast Track Drug Development Program is designed to facilitate frequent interactions with the FDA review team to expedite the clinical development and review of a New Drug Application, or NDA, for medicines with the potential to treat serious or life-threatening conditions and address unmet medical needs for such disease or conditions. It also provides the opportunity to submit sections of an NDA on a rolling basis before a sponsor submits the complete application. Genzyme is currently enrolling patients in its Phase 2a trial of GZ/SAR402671, and plans to enroll nine treatment-nave male adult patients with Fabry disease in this international, multicenter study.
April 27, 2015
06:19 EDTSNYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:32 EDTALNYJPMorgan Smid biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 22, 2015
10:02 EDTSNYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded on post-merger outlook at Bernstein... Amazon.com (AMZN) upgraded to Buy, price target raised to $450 at Monness Crespi... BNP Paribas (BNPQY) upgraded to Overweight from Equal Weight at Morgan Stanley... Dolby (DLB) upgraded to Overweight from Neutral at JPMorgan... First Defiance (FDEF) upgraded to Outperform from Market Perform at Raymond James... Gran Tierra (GTE) upgraded to Buy from Neutral at Dundee... Grupo Aval (AVAL) upgraded to Buy from Neutral at Goldman... Manhattan Associates (MANH) upgraded to Buy from Hold at Benchmark Co.... Marriott (MAR) upgraded to Buy from Neutral at MKM Partners... Masco (MAS) upgraded to Outperform from Market Perform at FBR Capital... Nokia (NOK) upgraded on post-merger outlook at Bernstein... Packaging Corp. (PKG) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Sector Perform from Underperform at RBC Capital... Rogers Communications (RCI) upgraded to Buy from Neutral at BofA/Merrill... Sanofi (SNY) upgraded to Neutral from Sell at Citigroup... Select Comfort (SCSS) upgraded to Outperform from Neutral at Wedbush... UniCredit (UNCFF) upgraded to Buy from Sell at Berenberg... Zions Bancorp (ZION) upgraded to Outperform from Market Perform at FBR Capital.
07:07 EDTSNYEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
06:52 EDTSNYSanofi upgraded to Neutral from Sell at Citigroup
Subscribe for More Information
April 21, 2015
11:01 EDTALNYAlnylam price target raised to $145 from $125 at Leerink
Subscribe for More Information
09:22 EDTALNYOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTSNYGenzyme initiates Phase 2a trial to evaluate pharmocodynamics of GZ/SAR402671
Subscribe for More Information
06:59 EDTALNYAlnylam to host conference call
Subscribe for More Information
06:03 EDTALNYAlnylam announces positive results from Phase 2 study with patisiran
Subscribe for More Information
April 20, 2015
09:20 EDTSNYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:18 EDTALNYAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use